Acrivon Competitors and Similar CompaniesClear all
Acrivon's competitors and similar companies include CARsgen Therapeutics and Numab.
 Acrivon Acrivon (also known as Acrivon Therapeutics) is a clinical-stage oncology company that leverages a precision medicine platform called Acrivon Predictive Precision Proteomics (AP3) for the development of a drug pipeline. |  CARsgen Therapeutics CARsgen Therapeutics is a clinical-stage immune-oncology company that develops a new chimeric T-cell antigen receptor for liver, lung, stomach and brain cancers treatment. | ||
Founding Date | Founding Date 2018 | Founding Date 2014 | Founding Date 2011 |
Type | Type Public | Type Private | Type Private |
Tags | |||
Locations | Locations Watertown, US HQ Lund, SE | Locations Shanghai, CN HQ Beijing, CN Shanghai, CN Shanghai, CN Bellaire, US | Locations Wädenswil, CH HQ |
Employees | Employees 415% increase | Employees 100 | Employees 681% decrease |
Funding | |||
Latest funding round | Latest funding round N/A | Latest funding round $ 186m (over 5 years ago) | Latest funding round $ 110m (about 5 years ago) |
Total funding raised | Total funding raised N/A | Total funding raised $ 276m | Total funding raised $ 132.3m |
For sources of this data, please see the company profile
View Company Profiles
CARsgen Therapeutics
HQ
Shanghai, CN
Employees
100
CARsgen Therapeutics is a clinical-stage immune-oncology company that develops a new chimeric T-cell antigen receptor for liver, lung, stomach and brain cancers treatment.
View company
Numab
HQ
Wädenswil, CH
Employees
68↓ 1% decrease
Numab Therapeutics is an oncology-focused biopharmaceutical company.
View company